期刊文献+

大剂量环磷酰胺联合粒细胞集落刺激因子动员多发性骨髓瘤造血干细胞的价值研究 被引量:1

High-dose cyclophosphamide with granulocyte colony-stimulating factor for mobilization of autologous peripheral blood stem cells in patients with multiple myeloma
原文传递
导出
摘要 目的研究大剂量环磷酰胺(HD—CTX)联合粒细胞集落刺激因子(G—CSF)在多发性骨髓瘤(MM)造血干细胞动员中的临床疗效和安全性。方法选择2006年6月至2010年9月中山大学附属第一医院血液科36例MM患者,全部患者接受HD—CTX联合G—CSF动员,CTX3~5g/m2,第1天,G—CSF300μg/d第2天起直到干细胞采集结束。结果35例(97.2%)动员成功,其中31例第一次动员即成功,4例第二次动员成功。干细胞采集的中位时间为第11(9~13)天,22例(62.9%)患者采集1次,13例(37.1%)患者采集2次。采集的单个核细胞(MNC)数为(4.49±1.71)×10^8/kg,CD34+细胞数为(3.21±1.87)×10。/kg。7例疗效在动员后得到进一步提高。动员的非血液系统副反应包括恶心、呕口王11例(26.8%)、腹痛腹泻5例(12.2%)、发热7例(17.1%)、骨痛4例(9.8%)等。只有1例因感染影响干细胞采集。结论HD—CTX联合G—CSF是MM造血干细胞动员的安全有效的方法。 Objective To explore the efficacy and safety of high-dose cyclophosphamide (CTX)with granuloeyte colony-stimulating factor for mobilization of autologous peripheral blood stem cells in patients with muhiple myeloma. Methods 36 cases with muhiple myeloma receiced HD-CTX 3 × 5 g/m2 on day 1 and G-CSF 300 txg/d was used on day 2 and given daily subcutaneously until stem cells collection was completed. Results Mobilization was successful in 35/36 (97.2%)patients. Collection was started on days 11 (9 - 13 ). Enough stem cells was acqired in 22 cases(62. 9% ) by one leukopherese. However, 13 eases(37. 1% ) need twice. The mean number of MNC was(4. 49 ±2 1.71 )× 10^8/kg and CD34 + was(3.21 ± 1.87 ) × 10^6/kg. The clinical effects of 7/ 35 patients were improved after mobilization. Non-hematological adverse events included nausea and vomiting 11 (26. 8% ) ,diarrhea 5(12. 2% ) ,fever 7(17. 1% ) ,bone pain 4(9. 8% ). All of these adverse reactions could be controlled with routine supportive treatmemt. Only one failue to mobilization due to infection. Conclusion HD-CTX with granulocyte colony-stimulating factor is an effective and safe mobilizing regimen for autologous peripheral blood stem progenitor cells in patients with multiple myeloma.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2011年第7期530-532,共3页 Chinese Journal of Practical Internal Medicine
基金 广东省自然科学基金(8151008901000064)
关键词 多发性骨髓瘤 大剂量环磷酰胺 粒细胞集落刺激因子 multiple myeloma high-dose cyclophosphamide G-CSF
  • 相关文献

参考文献7

  • 1Gertz MA, Kumar SK, Lacy MQ, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma[J]. Bone Marrow Transplant ,2009,43 ( 8 ) :619 - 625.
  • 2Nakasone H,Kanda Y, Ueda T, et al. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma [J]. Am J Hemato1,2009,84 ( 12 ) : 809 - 814.
  • 3Gojo I, Guo C, Sarkodee-Adoo C, et al. High-dose cyclophospha- mide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple rnyeloma: efficacy and toxicity [ J ]. Bone Marrow Transplant,2004,34 ( 1 ) :69 - 76.
  • 4武永吉.多发性骨髓瘤[M]//张之南,沈悌.血液病诊断及疗效标准.3版.北京:科学出版社,2007:232-235.
  • 5Blade J,Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant [ J ]. Br J Haematol, 1998,102 ( 5 ) : 1115 - 1123.
  • 6Goldschmidt H, Hegenbart U, Haas R, et al. Mobilization of pe- ripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7/m^2 ) and granulocyte colony-stimulating factor in patients with multiple myeloma [J]. Bone Marrow Transplant, 1996, 17 ( 5 ) : 691 - 797.
  • 7de la Rubia J, Bonanad S, Palau J, et al. Rapid progression of mul- tiple myeloma following G-CSF mobilization [ J ]. Bone Marrow Transplant, 1994,14 ( 3 ) :475 - 476.

共引文献13

同被引文献22

  • 1JEMAL A, BRAY F,CENTER M M,et al. Global cancer statistics [J]. CA Cancer J Clin, 2011,61: 69-90.
  • 2RICHARDSON P,WELLER E,LONIAL Sv et al. Lenalidomide , bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma [J]. Blood,2010, 116: 679-686.
  • 3BARLOGIE B, HALL R, ZANDER A, et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma [J]. Blood, 1986 ,67: 1298- 30l.
  • 4ATTAL M,HAROUSSEAU J L,STOPPA A M,et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome [J]. N Engl J Med, 1996 ,335: 91-97.
  • 5ANDERSON K C,ALSINA M,BENSINGER W,et al. NCCN clinical practice guidelines in oncology: multiple myeloma [J]. J Natl Compr Cane Netw , 2009 ,7: 908- 942.
  • 6ABDELKEFI A,LADEB S,TOMAN L, et al. Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multi-center randomized clinical trial [J]. Blood, 2008, 111: 1805-1810.
  • 7LAHUERTA J J, MATEOS M V, MARTINEZ L J,et al. Influence of pre- and post- transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival [J]. J Clin Oncol, 2008 ,26: 5775-5782.
  • 8BENSON D M J R, PANZNER K HAMADANI M, et al.Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma [J]. Leuk lymphoma,2010,51 :243-251.
  • 9GIRALT S,STADTMAUER E A,HAROUSSEAU J L, et al, International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixaior (AMD 3100) [J]. Leukemia, 2009 ,23: 1904-1912.
  • 10LAHUERTA J J, GRANDE C, MARTINEZ L J, et al. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma[J]. Leuk Lymphoma, 2002,43: 67 - 74.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部